LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., (“Synageva”) (NASDAQ:GEVA) a clinical stage biopharmaceutical company developing therapeutic products for rare disorders announced that it has completed enrollment in the first clinical trial of enzyme replacement for Lysosomal Acid Lipase (LAL) Deficiency. Interim data from this clinical trial of SBC-102 in patients with LAL Deficiency has been selected as an oral presentation at the upcoming Lysosomal Disorder Network (LDN) WORLD Symposium being held February 8-10, 2012 in San Diego, CA. The Phase I/II study was designed to evaluate the safety and tolerability of SBC-102 administered weekly in patients with liver dysfunction due to late onset LAL Deficiency. The study is fully enrolled with all patients completing their scheduled infusions. There have been no treatment-related serious adverse events, infusion-related reactions or withdrawals reported to date, and patients have begun transitioning into the extension study.
